Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.58 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.58 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.65 |
| ▸ | PRMT1 | Q99873 | 4/20 | 0.65 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009609 | 0.98 | CARM1 (0.63) | CARM1PRMT1HTR1ADRD2IDO1 | |
| SCHEMBL1412912 | 0.89 | HTR1A (0.73) | HTR1ADRD2LTA4HPLA2G2AABCB1 | |
| SCHEMBL2989204 | 0.87 | HTR1A (0.77) | HTR1ADRD2LTA4HPLA2G2AABCB1 | |
| SCHEMBL2985019 | 0.79 | CARM1 (0.55) | CARM1PRMT1HTR1ADRD2IDO1 | |
| SCHEMBL16825351 | 0.79 | HTR1A (0.69) | HTR1ADRD2LTA4HPLA2G2AABCB1 | |
| Hydrochloric Acid SCHEMBL6482842 | 0.76 | HTR1A (0.65) | CARM1PRMT1HTR1ADRD2LTA4H | |
| SCHEMBL17583859 | 0.76 | LTA4H (0.58) | HTR1ADRD2LTA4HPLA2G2AABCB1 | |
| SCHEMBL19141517 | 0.76 | RXRA (0.61) | CARM1PRMT1HTR1ADRD2TAAR1 | |
| Hydrochloric Acid SCHEMBL8318929 | 0.76 | PTGER1 (0.67) | HTR1ADRD2ABCB1DHFRPTGER1 | |
| SCHEMBL20249529 | 0.76 | FFAR1 (0.65) | LTA4HPLA2G2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7087644-B1 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1216225-B1 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | HTR1A 1924/4885DRD2 2331/4885HRH1 1776/4885 |
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | HTR1A 1924/4885DRD2 2331/4885HRH1 1776/4885 |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | DDC, AADAT, PTGIS | HTR1A 1924/4885DRD2 2331/4885HRH1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.